



Irish Life
health

Private Room Fees Ground Rules

2020

In May 2019, Irish Life Health to recognise the work done by consultants in their private rooms, where they may have invested in additional equipment or facilities to provide an enhanced experience to their patients and to avoid an admission into a hospital setting, introduced a "Private Room Fee" code.

This Private room fee was introduced for selected procedures (as outlined below) in Dermatology, Plastic Surgery, Ophthalmology, Chemotherapy and Haematology. The additional code(s) will only be paid where no hospital or other bill is involved/ received and will be paid at 100% (multiplier rules does not apply).

This code may be claimed in conjunction with the professional fee procedure code, only when the consultant has performed the procedure in their own rooms/ suite (based on the consultant decisions regarding appropriateness and safety).

For these selected codes, when the consultant opts to undertake the procedure in the hospital, billing and claim submission remains as per usual claims submission process. Consultants are required to submit their claim form, billing both the procedure code and the appropriate "Private Rooms" code, specific to their discipline.

CODE	DESCRIPTION
441598	Consultant Haematologist Private Rooms Technical Fee
441599	Consultant Oncologist Private Rooms Technical Fee
666599	Consultant Ophthalmologist Private Rooms Technical Fee
811599	Consultant Dermatologist Private Rooms Technical Fee
856599	Consultant Plastic Surgeon Private Rooms Technical Fee

In the instance that the procedure includes a specified drug, the consultant may make application (post Covid 19 period), such as in the case of intravitreal injections or a number of infusions, for Irish Life Health to recognise the Company as a recognised centre for such treatments. Thus subject to contract and agreement, Irish Life Health will reimburse the consultant for the drug at the specified rate, as outlined in the Irish Life Health standardised drug list, at manufacturer's rates, plus VAT, plus a mark-up depending on whether the drug is a biosimilar or a generic.

Drugs need to be administered and invoiced in the most efficient manner to eliminate waste, abuse and error. The list is subject to updating as and when drug prices change (in line with the IPHA agreement) and as and when new drugs enter the market.

All drugs listed in the procedure codes below will be reimbursed by Irish Life Health. Please contact consultantcontracts@irishlifehealth.ie for a comprehensive copy of the drugs available for reimbursement and the rates thereof.

Procedures where the Private Room codes may be claimed in conjunction with the professional fee, are outlined below and are subject to change based on further input and feedback from the consultants. Should you wish to discuss this further, or if you have any additional recommendations to make, we would be more than willing to review this. Please email consultantcontracts@irishlifehealth.ie with your requests.

CONDITIONS OF PAYMENT

The claiming of benefit will continue on the basis of a fully completed Irish Life Health claim form from the primary treating consultant.

HAEMATOLOGY CODES

CODE	DESCRIPTION
666599	Consultant Ophthalmologist Private Rooms Technical Fee
2512	Left eye, intravitreal injection of Lucentis for the treatment of neovascular (wet) age-related macular degeneration (AMD) (I.P.)
2513	Right eye, intravitreal injection of Lucentis for the treatment of neovascular (wet) age-related macular degeneration (AMD) (I.P.)
2516	Left eye, intravitreal injection of Lucentis for the treatment of visual impairment due to diabetic macular oedema (DME) (I.P.)
2517	Right eye, intravitreal injection of Lucentis for the treatment of visual impairment due to diabetic macular oedema (DME) (I.P.)
2518	Left eye, intravitreal injection of Lucentis for the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) (I.P.)
2519	Right eye, intravitreal injection of Lucentis for the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) (I.P.)
2541	Intravitreal implantation of Ozurdex (Dexamethasone) for treatment of adult patients with macular oedema following either Branch Retinal Vein Occlusion (BRVO) or Central Retinal Vein Occlusion (CRVO) (I.P.)
2543	Intravitreal implantation of Ozurdex (Dexamethasone) for treatment of adult patients with inflammation of the posterior segment of the eye presenting as non-infectious uveitis (I.P.)
2551	Left eye, intravitreal injection of Avastin for treatment of visual impairment due to diabetic macular oedema (DME) (I.P.)
2552	Right eye, intravitreal injection of Avastin for treatment of visual impairment due to diabetic macular oedema (DME) (I.P.)
2553	Left eye, intravitreal injection of Avastin for the treatment of neovascular (wet) age-related macular degeneration (AMD) (I.P.)
2554	Right eye, intravitreal injection of Avastin for the treatment of neovascular (wet) age-related macular degeneration (AMD) (I.P.)
2559	Intravitreal injection of Eylea (Aflibercept) (bilateral) for the treatment of visual impairment due to diabetic macular oedema (DME) (I.P.)
2561	Left eye, intravitreal injection of Eylea (Aflibercept) for the treatment of neovascular (wet) age-related macular degeneration (AMD) (I.P.)
2562	Right eye, intravitreal injection of Eylea (Aflibercept) for the treatment of neovascular (wet) age-related macular degeneration (AMD) (I.P.)
2563	Intravitreal injection of Eylea (aflibercept) (bilateral) for the treatment of neovascular (wet) age-related macular degeneration (AMD) (I.P.)
2564	Left eye, intravitreal injection of Eylea (Aflibercept) for the treatment of visual impairment due to diabetic macular oedema (DME) (I.P.)
2567	Left eye, intravitreal injection of Avastin for the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (RVO) (I.P.)
2568	Right eye, intravitreal injection of Avastin for the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (RVO) (I.P.)
2569	Right eye, intravitreal injection of Eylea (Aflibercept) for the treatment of visual impairment due to diabetic macular oedema (DME) (I.P.)
2571	Left eye, intravitreal injection of Eylea (Aflibercept) for the treatment of visual impairment due to macular oedema secondary to central retinal vein occlusion (CRVO) or or branch retinal vein occlusion (I.P.)
2572	Right eye, intravitreal injection of Eylea (Aflibercept) for the treatment of visual impairment due to macular oedema secondary to central retinal vein occlusion (CRVO) or branch retinal vein occlusion (I.P.)
669514	Bilateral, intravitreal injection of Lucentis for the treatment of neovascular (wet) age-related macular degeneration (AMD) (I.P.)
669518	Bilateral, intravitreal injection of Lucentis for the treatment of visual impairment due to diabetic macular oedema (DME) (I.P.)
669520	Bilateral, intravitreal injection of Lucentis for the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) (I.P.)
669542	Right eye, intravitreal implantation of Ozurdex (Dexamethasone) for treatment of adult patients with macular oedema following either Branch Retinal Vein Occlusion (BRVO) or Central Retinal Vein Occlusion (CRVO) (I.P.)
669543	Bilateral, intravitreal implantation of Ozurdex (Dexamethasone) for treatment of adult patients with macular oedema following either Branch Retinal Vein Occlusion (BRVO) or Central Retinal Vein Occlusion (CRVO) (I.P.)

CODE	DESCRIPTION
669544	Right eye, intravitreal implantation of Ozurdex (Dexamethasone) for treatment of adult patients with inflammation of the posterior segment of the eye presenting as non-infectious uveitis (I.P.)
669545	Bilateral, intravitreal implantation of Ozurdex (Dexamethasone) for treatment of adult patients with inflammation of the posterior segment of the eye presenting as non-infectious uveitis (I.P.)
669551	Bilateral, intravitreal injection of Avastin for treatment of visual impairment due to diabetic macular oedema (DME) (I.P.)
669555	Bilateral, intravitreal injection of Avastin for the treatment of neovascular (wet) age-related macular degeneration (AMD) (I.P.)
669569	Bilateral, intravitreal injection of Avastin for the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (RVO) (I.P.)
669573	Bilateral, intravitreal injection of Eylea (aflibercept) for the treatment of visual impairment due to macular oedema secondary to central retinal vein occlusion (CRVO) or branch retinal vein occlusion (I.P.)
669580	Left eye, implantation of 190mcg Iluvien flucuronide acetone device (I.P.)
669581	Right eye, implantation of 190mcg Iluvien flucuronide acetone device (I.P.)

DERMATOLOGY PROCEDURES

CODE	DESCRIPTION
811599	Consultant Dermatologist Private Rooms Technical Fee
1531	Biopsies of the skin, subcutaneous tissue and/ or mucous membrane including simple closure (I.P.) (the areas biopsied must be specified on the claim form)
1575	Basal cell carcinoma/ squamous cell carcinoma/ non melanoma - simple excision
1591	Hydradenitis suppurativa, excision and suture

PLASTIC/ RECONSTRUCTIVE PROCEDURES

CODE	DESCRIPTION
856599	Consultant Plastic Surgeon Private Rooms Technical Fee
1603	Wounds greater than 7.5cm in total length, suture or staple of lacerated or torn tissue, single or multi layered closure with or without irrigation or debridement (I.P.)
4504	Nipple - areola tattooing performed by a consultant (one or more visits)
4538	Treatment of superficial wound dehiscence; simple closure with or without packing (single layer closure)
4546	Keloids and hypertrophic scars (I.P.)
4722	Dupuytren's contracture, using Collagenase Clostridium Histolyticum (Xiapex), palms and fingers (I.P.)
4920	Fracture of nose, digital closed reduction
4925	Fracture of nose, instrumental closed reduction
4926	Fracture of nose, instrumental closed reduction with plaster of paris fixation
4927	Fracture of nose, instrumental closed reduction with reduction of septum and plaster of paris fixation
4937	Excision of benign or malignant lesion(s), any area; adjacent tissue transfers or rearrangement, where there is the requirement for more than 1 layer of deep or deep dermal sutures for effective closure
4938	Excision of benign or malignant lesion(s), any area; adjacent tissue transfer or rearrangement, where there is the requirement for quilting or mattress sutures for effective closure
4983	Botox for hyperhidrosis (I.P.)
15872	Laser treatment to port wine stains only, one or more sessions - non General Anaesthetic

ONCOLOGY & HAEMATOLOGY

CODE	DESCRIPTION
441599	Consultant Oncologist Private Rooms Technical Fee
441598	Consultant Haematologist Private Rooms Technical Fee

CODE	DESCRIPTION
1571	Intravenous infusion of Ferinject (ferric carboxymaltose) for patients with resistant iron deficiency anaemia (maximum of two treatments per year)
1572	Intravenous infusion of Monover (iron isomaltoside) for patients with resistant iron deficiency anaemia
1594	Infusion of Tocilizumab (RoActemra)
1606	Intravenous infusion of Zoledronic Acid (Aclasta) for treatment of osteoporosis in post-menopausal women and men at increased risk of fracture including those with a recent low trauma hip fracture, who fail to tolerate oral bisphosphonates
1607	Intravenous infusion of Abatecept with Methotrexate for the treatment of moderate to severe rheumatoid arthritis in adult patients, and moderate to severe active polyarticular juvenile idiopathic arthritis in paediatric patients six years of age and older, who have had an insufficient response or intolerance to other disease-modifying anti-rheumatic drugs including at least one tumour necrosis factor (TNF) inhibitor
1609	Consultation and assessment by a consultant Medical Oncologist of a patient on a course of first line cytotoxic oral anti-cancer agents (I.P.)
1611	Intravenous infusion of Fabrazyme for patients with a confirmed diagnosis of Fabry's disease
1613	Intravenous infusion therapy for severe neurological disorders or auto-immune disease, not elsewhere specified and for Hurler's and Hunter's disease; by Consultant Neurologists, Immunologists, Rheumatologists, Haematologists, Nephrologists, Paediatricians, Respiratory Physicians, Gastroenterologists, General Physicians and Endocrinologists registered with Irish Life Health
1614	Infusion of Mitoxantrone (Novantrone) for patients with secondary progressive multiple sclerosis, progressive-relapsing multiple sclerosis and worsening relapsing-remitting multiple sclerosis
1623	Intravenous immunoglobulin for patients with myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, multifocal motor neuropathy with conduction block and Guillain-Barre syndrome
1624	Intravenous infusion of zoledronic acid
1628	Cytotoxic Chemotherapy by subcutaneous injection requiring monitoring in a hospital setting
1629	Intravenous infusion of Pamidronate (Aredia)
1633	Infusion of Infliximab or biosimilar
1636	Intravenous immunoglobulin for patients with a haematological malignancy or immune deficiencies
1643	Intravenous iron infusion for patients with resistant iron deficiency anaemia
1664	Insulin stress test (IST) to include initial consultation for a new patient or major reassessment of an established patient, in addition intravenous administration of insulin, sampling for basal level setting and all necessary sampling and monitoring of the patient during the procedure (I.P.)
1677	Supervision and management by a consultant of a patient receiving cytotoxic chemotherapy with Velcade or Vidaza by injection requiring monitoring in a hospital setting
1682	Administration of Trastuzumab (Herceptin or biosimilar) by subcutaneous injection, subsequent injection, requiring monitoring for two hours in a hospital setting
16091	Consultation and assessment by a consultant Medical Oncologist of a patient on a course of second line cytotoxic oral chemotherapy agents (I.P.)
16092	Consultation and assessment by a consultant Medical Oncologist of a patient on a course of third line cytotoxic oral chemotherapy agents (I.P.)
16191	Sub-cutaneous cytotoxic chemotherapy (where not otherwise specified)
309011	Infusion of MabThera with glucocorticoids for the induction of remission in adult patients with severe, active Wegners Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA)
825000	Biopsies of the skin, subcutaneous tissue and/ or mucous membranes, any method multiple lesions (I.P.)